Effects of remazolam combined with etomidate anesthesia on stress response and quality of recovery after non-cardiac surgery in elderly patients: a prospective randomized controlled trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400088496

Enrollment

Unknown

Registered

2024-08-20

Start date

2024-08-20

Completion date

Unknown

Last updated

2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elderly non-cardiac surgery patients

Interventions

Remazolam combined with etomidate (RE) group:Anesthesia induction: After full oxygenation and denitrogenation, patients were slowly injected with remazolam 0.2 mg/kg+ etomidate 0.1-0.2 mg/kg, Sufentan

In the RE group, intravenous infusion of remazolam 0.4 mg/(kg·h), etomidate 0.2-0.4 µg/mL (adjusted according to the CSI value) were used to maintain CSI 40-55, patient status index (PSI) 35-50, and t

Etomidate (RE) group:Anesthesia induction: Patients were slowly injected with etomidate 0.3 mg/kg (group E) Sufentanil 0.3-0.4 µg/kg and cisatracurium 0.15 mg/kg. Anesthesia maintenance: intravenous p

Maintain CSI 40-55, patient status Index (PSI) 35-50, and maintain heart rate and MAP changes no more than 20% of the baseline value.

Eligibility

Sex/Gender

All

Age

60 Years to 80 Years

Inclusion criteria

Inclusion criteria: Elderly patients were selected for non-cardiac surgery under general anesthesia, age 60 to 80 years old, BMI 18.5 to 28.0 kg/m^2, ASA grade I to III, and the expected time of surgery was 1 to 2 hours.

Exclusion criteria

Exclusion criteria: 1. Severe liver, kidney, heart and other organ dysfunction, severe hypertension (higher than 180/110mmHg) and adrenal cortex dysfunction; 2. Severe respiratory, metabolic, immune or infectious diseases; 3. Coagulation function, neurological function, cognitive function impairment; 4. Allergic history or history of adverse reactions to anesthetic drugs or fat emulsions used in this study; 5. Unable to understand the written information or informed consent of the trial.

Design outcomes

Primary

Measure	Time frame
Time for patient to follow instructions (starting from the end of the procedure when the medication is stopped);	—

Secondary

Measure	Time frame
CSI over 80 hours;Tracheal catheter removal time;	—

Countries

China

Contacts

Public ContactFeng Yan

Affiliated Hospital of North Sichuan Medical College

fengyan@nsmc.edu.cn+86 158 8262 6422

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026